G1 Therapeutics (GTHX) FCF conversion US GAAP (year values) |
|||||||||
| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | LTM ? | 5 years average | |||
| FCF conversion, % | 87.7% | 92.7% | 95.7% | 111.8% | 112.0% | ||||
| Changes by years, y/y, % | +5pp | +3pp | +16pp | 94% | |||||
G1 Therapeutics. FCF conversion, %
G1 Therapeutics. FCF conversion, changes, pp
G1 Therapeutics (GTHX) FCF conversion US GAAP (quarter values) |
||||||||
| FY2023Q2 | FY2023Q3 | FY2023Q4 | FY2024Q1 | FY2024Q2 | LTM ? | |||
| FCF conversion, % | 109.5% | 70.2% | 165.5% | 109.6% | 201.1% | 112.0% | ||
| Changes by years, y/y, % | +4pp | -30pp | +64pp | -10pp | +92pp | |||
| Changes by quarters, q/q, % | -10pp | -39pp | +95pp | -56pp | +92pp | |||